InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Saturday morning. The brokerage issued a sell rating on the stock.

InspireMD Stock Up 2.2 %

NSPR opened at $2.80 on Friday. The stock has a market cap of $69.80 million, a price-to-earnings ratio of -3.68 and a beta of 0.90. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.85. The business has a 50 day moving average of $2.73 and a 200-day moving average of $2.51.

InspireMD (NYSE:NSPR) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The business had revenue of $1.74 million for the quarter, compared to analyst estimates of $1.74 million. During the same period in the prior year, the business earned ($0.24) EPS. As a group, analysts expect that InspireMD will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

Several hedge funds have recently bought and sold shares of the stock. McKinley Carter Wealth Services Inc. acquired a new stake in InspireMD during the 4th quarter worth approximately $28,000. Mesirow Financial Investment Management Inc. bought a new position in InspireMD during the 1st quarter worth $71,000. Finally, Rosalind Advisors Inc. lifted its holdings in shares of InspireMD by 266.4% during the second quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock worth $6,272,000 after buying an additional 1,827,579 shares in the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.